Vertex Pharmaceuticals Q1 2024 Financial Results and Pipeline Update

Vertex Pharmaceuticals presents first quarter 2024 financial results and strategic updates on its pipeline programs, including advancement in cystic fibrosis, acute pain, and cell therapy programs. The presentation covers CEO perspectives on pipeline development, commercial updates, and financial guidance for full-year 2024, with discussions on key programs including suzetrigine, VX-880 for type 1 diabetes, and CASGEVY for blood disorders.